FDNA

745 Atlantic Avenue
8th Floor
Boston
Massachusetts
02111
United States

Tel: 617-412-7000 or 44-117-230-2405

About FDNA

FDNA’s mission is to save lives and improve the quality of life of patients with rare or difficult-to-diagnose genetic syndromes. FDNA has developed the proprietary Facial Dysmorphology Novel Analysis (FDNA®) technology. This cutting-edge technology facilitates the detection of facial dysmorphic features and recognizable patterns of human malformations from facial photos.
YEAR FOUNDED:
2010
LEADERSHIP:
Founders: Moti Shniberg and Lior Wolf
CEO: Dekel Gelbman
JOBS:
Please click here for FDNA job opportunities.

8 articles about FDNA

FDNA and PerkinElmer Announce Collaboration to Offer Enhanced Genetic Testing Augmented by AI and Facial Analysis

6/25/2019

Together, they will offer genomic services paired with next-generation phenotyping technologies for more efficient and accurate diagnoses.
FDNA Announces Groundbreaking Results with The Focus Foundation as Part of the Genomics Collaborative

5/4/2018

FDNA, in collaboration with The Focus Foundation, announces the successful recognition of the facial phenotype of 49,XXXXY (“49ers”) syndrome.
FDNA Expands Leadership Team with Addition of Chief Medical Officer and Chief Data Science Officer

4/9/2018

FDNA, developer of the Face2Gene suite of next-generation phenotyping (NGP) applications, announces at the American College of Medical Genetics and Genomics annual meeting the appointment of Dr. Karen Gripp to Chief Medical Officer and Dr. Peter Krawitz to Chief Data Science Officer.
FDNA Launches Genomics Collaborative® with Multiple Research Partners Globally.

2/28/2018

FDNA today announces the launch of the Genomics Collaborative along with multiple medical research collaborations as part of a new global initiative.
FDNA Grants Manchester Centre for Genomic Medicine at Saint Mary’s Hospital, UK as Center of Research Excellence; Advancing Next-Generation Phenotyping for Genetics Evaluations

2/6/2018

The grant provides funding to researchers to advance next-generation phenotyping (NGP) and facial analysis technology at luminary sites working on precision medicine.
University Hospital Bonn Launches New Technology to Help Geneticists Worldwide Find the Genetic Cause of Rare Syndromes

11/7/2017

Through a partnership with Boston-based FDNA, clinicians worldwide can now instantly upload qualifying, de-identified case information to IGSB for a full assessment, including facial analysis and genetic testing.
University Hospital Bonn Announces New Technology To Advance Ability to Diagnose Rare Genetic Diseases in Children

11/7/2017

Today, the Institute for Genome Statistics and Bioinformatics, IGSB, and the Institute of Human Genetics, IHG, Bonn, announce a new initiative to further precision medicine through integration with FDNA’s Face2Gene suite of applications.
FDNA Launches New Face2Gene Suite Of Phenotyping Apps To Aid In Identification And Evaluation Of Rare And Ultra-Rare Genetic Disorders

10/18/2016